Shares rose 14.0% as the market rewarded Novavax’s clear progress in expanding high-value partnerships, particularly with big pharma like Pfizer and Sanofi, signaling confidence in its capital-efficient, licensing-driven growth strategy rather than direct product sales.

• Novavax signed four new material transfer agreements (MTAs) including a significant oncology MTA with a top 10 global pharma company, marking expanded collaboration in difficult cancer targets.
• The company’s partnerships with Pfizer and Sanofi are positioned to generate billions in future milestone and royalty revenues, with Sanofi already contributing over $800 million in revenue to date.
• Strategy emphasizes capital-efficient growth by leveraging partners’ infrastructure and investment, reducing Novavax’s operational costs while focusing on R&D-led innovation.
• Management outlined a lean operating model aimed at driving down costs while supporting key R&D capabilities under new Head of R&D Bob Walker.
• The outlook centers on advancing current partnerships to clinical readiness and converting MTAs into licensing agreements, supporting long-term, diversified revenue streams.